Survival probability in relation to the IgVHmutational status
. | . | DOS . | . | . | PFI . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
IgVμstatus . | n . | Events . | HR (95% CI) . | P . | Events . | HR (95% CI) . | P . | ||||
Nonmutated | 15 | 7 | 0.19 (0.05−0.76) | .01 | 9 | 0.31 (0.11−0.84) | .02 | ||||
Mutated | 22 | 3 | NA | NA | 8 | NA | NA |
. | . | DOS . | . | . | PFI . | . | . | ||||
---|---|---|---|---|---|---|---|---|---|---|---|
IgVμstatus . | n . | Events . | HR (95% CI) . | P . | Events . | HR (95% CI) . | P . | ||||
Nonmutated | 15 | 7 | 0.19 (0.05−0.76) | .01 | 9 | 0.31 (0.11−0.84) | .02 | ||||
Mutated | 22 | 3 | NA | NA | 8 | NA | NA |
The number of patients (n) and events observed in each group, estimated HR computed via the univariate Cox model, and the associated P values are indicated.